At the news
? NEUTRALIMPACT 2/10 6-K filed Sep 8, 2026 at 07:47 ET
Genmab A/S filed a 6-K convening an Extraordinary General Meeting on October 7, 2026, to seek shareholder approval of the Board of Directors' remuneration for 2026, which remains unchanged from 2024 and 2025. The proposal was withdrawn at the March 2026 AGM, prompting extensive shareholder outreach; the Board recalibrated the compensation peer group to an equal mix of U.S. and European companies but retained current fee levels and the service-based RSU structure. This is a routine governance matter with no material financial impact on the company's operations or fundamentals.
- Genmab is holding an EGM on October 7, 2026, to vote on Board remuneration for 2026.
- The remuneration proposal was withdrawn at the March 19, 2026 AGM, leading to shareholder outreach covering over 60% of share capital.
- The Board recalibrated the peer group from 13 U.S. and 7 European companies to an equal mix of 10 U.S. and 10 European companies.
- Annual base fees and share-based RSU remuneration remain unchanged from 2024 and 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access